welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson drug startup launches gastric-cancer trial
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Multistage Vector Delivery of Sulindac and Silymarin for Prevention of Colon CancerFamilial adenomatous polyposis (FAP) is ...
-
Role of Ileostomy in Restorative ProctocolectomyRestorative proctocolectomy (RP) is the ...
-
Our Experience of Treatment of Cribriform Morular Variant of Papillary Thyroid Carcinoma; Difference in Clinicopatho...Cribriform-morular variant (CMV) is a co...
-
Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
-
Efficacy and Safety of Eflornithine (CPP-1X)/Sulindac Combination Therapy Versus Each as Monotherapy in Patients wit...BACKGROUND: Molecular studies suggest i...
-
Procedure for Construction of an IPAAhttps://o.quizlet.com/jDNbvWUyQJxevMasMm...
-
Surgical Treatment of Familial Adenomatous Polyposis: Ileorectal Anastomosis or Restorative Proctolectomy?CONTEXT : Controversy regarding the best...